More reads

• Ginkgo Bioworks raises $350 million fund for biotech spinouts. (Reuters)
• Andreessen Horowitz just promoted a VC rising star to figure out how software will transform healthcare. (Business Insider)
• Rebuilding Neil Woodford’s reputation ‘could take a decade.’ (Financial News)

Correction: Yesterday's issue mischaracterized the side effects of Novartis's new treatment for ocular disease. The drug led to four times as much eye inflammation as seen with Regeneron Pharmaceuticals' competing Eylea, not four times as much as placebo